Lutetium - 177 PSMA Therapy

Lutetium-177 PSMA Therapy is a targeted radioisotope therapy in Malaysia for selected patients with advanced prostate cancer. This treatment is designed to bind to prostate cancer cells through PSMA, or prostate-specific membrane antigen, and deliver radioactive energy directly to cancer cells with short-range exposure.

Available at Sunway Medical Centre, Sunway City Kuala Lumpur, Lutetium-177 PSMA Therapy may be considered for patients with advanced prostate cancer who are resistant or unsuitable to hormonal therapy, looking for an alternative to chemotherapy, or experiencing intolerable bone pain. As a targeted and minimally invasive treatment option, PSMA Therapy may help inhibit cancer cell growth, ease symptoms associated with the tumour, and support quality of life and survival in suitable patients.

Package pricing may vary depending on whether dosimetry is required, treatment planning, number of admission days, and individual patient condition. Suitability must be assessed by specialists after reviewing the patient’s diagnosis, imaging results, blood tests, previous treatment history, and overall health status.

Why Consider Lutetium-177 PSMA Therapy?

Advanced prostate cancer may require specialised treatment planning, especially when the disease has progressed despite hormonal therapy or when patients are unsuitable for certain treatment options. Lutetium-177 PSMA Therapy offers a targeted approach by directing radioactive treatment to prostate cancer cells that express PSMA.

Because the therapy is highly targeted, it may help reduce cancer activity while limiting exposure to surrounding tissues. For suitable patients, this treatment may support symptom relief, improve quality of life, and provide another option when standard treatments are limited or no longer effective.

Who May Benefit from Lutetium-177 PSMA Therapy?

You may consider discussing Lutetium-177 PSMA Therapy with a specialist if you:

• Have advanced prostate cancer
• Are resistant or unsuitable to hormonal therapy
• Are looking for an alternative to chemotherapy
• Experience intolerable bone pain related to prostate cancer
• Have been advised that your cancer may express PSMA
• Need targeted radioisotope therapy assessment in Malaysia
• Want to understand whether PSMA Therapy may support symptom control and quality of life

What Are the Benefits of Lutetium-177 PSMA Therapy?

Potential benefits may include:

• Highly targeted treatment
• No surgery or chemotherapy
• Minimally invasive treatment
• May help improve quality of life and survival
• Generally tolerable side effects for suitable patients

What is Lutetium-177 PSMA Therapy?
Lutetium-177 PSMA Therapy is a targeted radioisotope therapy for selected patients with advanced prostate cancer. It uses a radioactive compound that binds to PSMA-expressing prostate cancer cells and delivers short-range radiation to the cancer cells.

What is PSMA?
PSMA stands for prostate-specific membrane antigen. It is a protein commonly found at higher levels on prostate cancer cells, making it a useful target for certain imaging and treatment approaches.

Who may be suitable for Lutetium-177 PSMA Therapy?
This therapy may be considered for patients with advanced prostate cancer who are resistant or unsuitable to hormonal therapy, patients looking for an alternative to chemotherapy, or those experiencing intolerable bone pain.

Is Lutetium-177 PSMA Therapy chemotherapy?
No. Lutetium-177 PSMA Therapy is not chemotherapy. It is a targeted radioisotope therapy used for selected prostate cancer patients.

Is Lutetium-177 PSMA Therapy a surgery?
No. It is not surgery. The treatment is minimally invasive and is usually administered through intravenous infusion under specialist supervision.

What are the potential benefits of this therapy?
Potential benefits may include targeted treatment, no surgery or chemotherapy, symptom relief, improved quality of life, and generally tolerable side effects in suitable patients.

Does every prostate cancer patient qualify for this treatment?
No. Suitability depends on factors such as PSMA expression, cancer stage, imaging results, blood tests, kidney function, bone marrow reserve, and previous treatment history.

What is dosimetry in Lutetium-177 PSMA Therapy?
Dosimetry is a calculation used to estimate radiation dose delivered to the tumour and normal organs. Some treatment plans may include dosimetry, while others may not, depending on clinical recommendation and package selection.

Can international patients receive Lutetium-177 PSMA Therapy in Malaysia?
Yes. International patients may arrange assessment for Lutetium-177 PSMA Therapy at Sunway Medical Centre, Sunway City Kuala Lumpur through the International Patient Centre.

• This package is valid for International Patients only.
• Prices are subject to 6% Sales & Service Tax (SST) and may change without prior notice.
• Prices are based on per person basis, in Malaysian currency (RM).
• Upon completion of payment, cancellations are not permitted. However, we do accommodate rescheduling requests provided date fall within the campaign period.
• Confirmed orders are non-refundable and non-transferable.
• Prices are valid until 31 December 2026.
• The non-refundable deposit (RM92,400) shall be paid 3-4 weeks before treatment date
• Appointment booking must be made 7 days in advance.
• Screening slots are available Monday through Friday from 08:00 to 17:00 only. Please note that screenings are not available on Sundays and Public Holidays.
• Travelers are responsible for independently securing their own visas.
• Terms and conditions, as well as prices, are subject to change without prior notice.
• For enquiries, please contact our International Patient Centre via WhatsApp at +(60)19-200 9191 or email us at [email protected].